Gapping down
In reaction to disappointing earnings/guidance: CLBS -32.1%, (provides 2015 and 2016 revenue guidance; announces an increased focus of its strategic priorities ), FINL -16.2%, RECN -6%, COST -2.5%, WBA -2%, KBH -1.6%, SIG -1.4%,
M&A news: ATML -8.3% (Bloomberg reporting that Microchip (MCHP) is reconsidering its interest in Atmel amid their continued business struggles), .
Select China related names showing weakness: JKS -6.7%, BABA -5%, CSIQ -4.7%, SOHU -4.7%, JD -4.6%, BITA -4.6%, BIDU -4.6%, CMCM -4.6%, WBAI -4.4%, SFUN -4.3%, JMEI -4.2%, YY -3.9%
Select metals stocks trading lower: VALE -6.5%, BBL -6.3%, RIO -5.1%, MT -4.9%, FCX -4.4%, X -3.5%, AA -3.4%
Select oil/gas related names showing early weakness: WLL -9%, SSL -7.5%, BHP -6.3%, SDRL -6%, BP -5.2%, RDS.A -5.2%, PBR -4.8%, RIG -4.3%, KMI -3.9%, STO -3.5%, SLB -2.7%
Other news: TLOG -67.6% (announces that its Phase 2 study of birinapant co-administered with azacitidine in first line higher risk patients suffering from myelodysplastic syndromes did not demonstrate any clinical benefit over placebo), EPZM -23.3% (prices offering of 13,333,334 shares of its common stock at $9.00 per share), ARDX -15.1% (commences an underwritten public offering of up to $75 mln of shares of its common stock, updates guidance on the projected timing of its clinical trials for its lead product candidate, tenapanor ), GALE -13.2% (to offer shares of its common stock and warrants to purchase its common stock in an underwritten public offering), AKBA -11.5% (prices 7,250,000 shares of common stock at $9.00 per share), SAGE -6.8% (prices 3,157,894 shares of its common stock at $47.50 per share), ADMS -6.4% (prices offering 2,500,000 shares of its common stock at $23.00 per share), CEMP -6.2% (prices its downsized underwritten public offering of ~4.17 mln shares of its common stock at $24.00/share), PSDV -5.3% (proposed a common stock offering for an undisclosed amount), ACAD -4.6% (prices offering of 10,344,827 shares of its common stock at $29.00 per share), PRTA -2.9% (prices underwritten public offering of 2.25 mln of its ordinary shares at $53.00/share), ERI -2.3% (announced the departure of its COO and CFO)
Analyst comments: EXPD -7.8% (downgraded to Sell at UBS), EVDY -4.9% (downgraded to Hold from Buy at Stifel), ILMN -3.9% (downgraded to Market Perform from Outperform at Wells Fargo), PAYX -3.8% (downgraded to Underperform from Neutral at BofA/Merrill), APC -3.7% (downgraded to Hold from Buy at Deutsche Bank), CMG -3.2% (target lowered to $450 from $500 at Wedbush), HPQ-3% (downgraded to Market Perform from Outperform at Wells Fargo), AAPL -2.5% (target lowered to $130 at RBC Capital Mkts), BRCM -1.5% (downgraded to Mkt Perform from Outperform at Bernstein)
In reaction to disappointing earnings/guidance: CLBS -32.1%, (provides 2015 and 2016 revenue guidance; announces an increased focus of its strategic priorities ), FINL -16.2%, RECN -6%, COST -2.5%, WBA -2%, KBH -1.6%, SIG -1.4%,
M&A news: ATML -8.3% (Bloomberg reporting that Microchip (MCHP) is reconsidering its interest in Atmel amid their continued business struggles), .
Select China related names showing weakness: JKS -6.7%, BABA -5%, CSIQ -4.7%, SOHU -4.7%, JD -4.6%, BITA -4.6%, BIDU -4.6%, CMCM -4.6%, WBAI -4.4%, SFUN -4.3%, JMEI -4.2%, YY -3.9%
Select metals stocks trading lower: VALE -6.5%, BBL -6.3%, RIO -5.1%, MT -4.9%, FCX -4.4%, X -3.5%, AA -3.4%
Select oil/gas related names showing early weakness: WLL -9%, SSL -7.5%, BHP -6.3%, SDRL -6%, BP -5.2%, RDS.A -5.2%, PBR -4.8%, RIG -4.3%, KMI -3.9%, STO -3.5%, SLB -2.7%
Other news: TLOG -67.6% (announces that its Phase 2 study of birinapant co-administered with azacitidine in first line higher risk patients suffering from myelodysplastic syndromes did not demonstrate any clinical benefit over placebo), EPZM -23.3% (prices offering of 13,333,334 shares of its common stock at $9.00 per share), ARDX -15.1% (commences an underwritten public offering of up to $75 mln of shares of its common stock, updates guidance on the projected timing of its clinical trials for its lead product candidate, tenapanor ), GALE -13.2% (to offer shares of its common stock and warrants to purchase its common stock in an underwritten public offering), AKBA -11.5% (prices 7,250,000 shares of common stock at $9.00 per share), SAGE -6.8% (prices 3,157,894 shares of its common stock at $47.50 per share), ADMS -6.4% (prices offering 2,500,000 shares of its common stock at $23.00 per share), CEMP -6.2% (prices its downsized underwritten public offering of ~4.17 mln shares of its common stock at $24.00/share), PSDV -5.3% (proposed a common stock offering for an undisclosed amount), ACAD -4.6% (prices offering of 10,344,827 shares of its common stock at $29.00 per share), PRTA -2.9% (prices underwritten public offering of 2.25 mln of its ordinary shares at $53.00/share), ERI -2.3% (announced the departure of its COO and CFO)
Analyst comments: EXPD -7.8% (downgraded to Sell at UBS), EVDY -4.9% (downgraded to Hold from Buy at Stifel), ILMN -3.9% (downgraded to Market Perform from Outperform at Wells Fargo), PAYX -3.8% (downgraded to Underperform from Neutral at BofA/Merrill), APC -3.7% (downgraded to Hold from Buy at Deutsche Bank), CMG -3.2% (target lowered to $450 from $500 at Wedbush), HPQ-3% (downgraded to Market Perform from Outperform at Wells Fargo), AAPL -2.5% (target lowered to $130 at RBC Capital Mkts), BRCM -1.5% (downgraded to Mkt Perform from Outperform at Bernstein)